Differential effects of the oncogenic BRAF inhibitor PLX4032 (vemurafenib) and its progenitor PLX4720 on ABCB1 function.

PURPOSE The clinically approved oncogenic BRAF inhibitor PLX4032 (vemurafenib) was shown to be a substrate of the ATP-binding cassette (ABC) transporter ABCB1. Here, we compared PLX4032 and its structurally closely related precursor compound PLX4720 for their interference with ABCB1 and the ABCB1-mediated compound transport using docking and cell culture experiments. METHODS For the docking study of PLX4032 and PLX4720 with ABCB1, we analysed binding of both compounds to mouse Abcb1a and to human ABCB1 using a homology model of human ABCB1 based on the 3D structure of Abcb1a. Naturally ABCB1 expressing cells including V600E BRAF-mutated and BRAF wild-type melanoma cells and cells transduced with a lentiviral vector encoding for ABCB1 were used as cell culture models. ABCB1 expression and function were studied by the use of fluorescent and cytotoxic ABCB1 substrates in combination with ABCB1 inhibitors. RESULTS Docking experiments predicted PLX4032 to interact stronger with ABCB1 than PLX4720. Experimental studies using different cellular models and structurally different ABCB1 substrates confirmed that PLX4032 interfered stronger with ABCB1 function than PLX4720. For example, PLX4032 (20 µM) induced a 4-fold enhanced rhodamine 123 accumulation compared to PLX4720 (20 µM) in ABCB1-transduced UKF-NB-3 cells and reduced the IC₅₀ for the cytotoxic ABCB1 substrate vincristine in this model by 21-fold in contrast to a 9-fold decrease induced by PLX4720. CONCLUSIONS PLX4032 exerted stronger effects on ABCB1-mediated drug transport than PLX4720. This indicates that small changes in a molecule can substantially modify its interaction with ABCB1, a promiscuous transporter that transports structurally different compounds.

[1]  K. Flaherty,et al.  Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Balázs Sarkadi,et al.  The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). , 2008, Drug discovery today.

[3]  K. Flaherty,et al.  BRAF, a target in melanoma , 2010, Cancer.

[4]  J. Otte,et al.  Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells. , 2010, Neoplasia.

[5]  Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells , 2012, Molecular and Cellular Biochemistry.

[6]  B. Sikic,et al.  Molecular Pathways: Regulation and Therapeutic Implications of Multidrug Resistance , 2012, Clinical Cancer Research.

[7]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[8]  A. von Deimling,et al.  Increased malignant behavior in neuroblastoma cells with acquired multi-drug resistance does not depend on P-gp expression. , 2005, International journal of oncology.

[9]  Geoffrey Chang,et al.  Understanding polyspecificity of multidrug ABC transporters: closing in on the gaps in ABCB1. , 2010, Trends in biochemical sciences.

[10]  Kam Y. J. Zhang,et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.

[11]  S. Vaidhyanathan,et al.  Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on the Brain Distribution of a Novel BRAF Inhibitor: Vemurafenib (PLX4032) , 2012, Journal of Pharmacology and Experimental Therapeutics.

[12]  P. Hirth,et al.  Vemurafenib: the first drug approved for BRAF-mutant cancer , 2012, Nature Reviews Drug Discovery.

[13]  B. Fehse,et al.  A multicolor panel of novel lentiviral "gene ontology" (LeGO) vectors for functional gene analysis. , 2008, Molecular Therapy.

[14]  Yue Weng,et al.  Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding , 2009, Science.

[15]  Michael Thomaschewski,et al.  RGB marking facilitates multicolor clonal cell tracking , 2011, Nature Medicine.

[16]  J. Beijnen,et al.  Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. , 2012, Molecular pharmaceutics.

[17]  Stephen G. Aller.  Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding , 2010 .

[18]  Jindrich Cinatl,et al.  Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3. , 2009, Cancer research.

[19]  S. Ambudkar,et al.  Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells. , 2013, Biochemical pharmacology.

[20]  M. Michaelis,et al.  Enzastaurin inhibits ABCB1-mediated drug efflux independently of effects on protein kinase C signalling and the cellular p53 status , 2015, Oncotarget.

[21]  Eszter Hazai,et al.  Predicting P-Glycoprotein-Mediated Drug Transport Based On Support Vector Machine and Three-Dimensional Crystal Structure of P-glycoprotein , 2011, PloS one.